Does sequencing order of antiandrogens in prostate cancer matter?

摘要

The optimal treatment sequences to maximize the clinical benefit for patients with metastatic castration-resistant prostate cancer (mCRPC) have not been defined. A new prospective, randomized trial on optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in mCRPC investigated whether one regimen resulted in superior outcomes.